Skip to main content
Premium Trial:

Request an Annual Quote

Xenometrix Receives Investment Funding

Premium

BOULDER, Colo.--Xenometrix, a biotech firm here with proprietary gene expression profiling technology and genotoxicology technology, received a cash infusion that the company said it expects will meet its operating requirements for two months. The infusion is the result of a letter of intent regarding a license for recently announced European patents and a US application and patents in the field of probe arrays.

The patents and application broadly cover methods and kits for producing gene expression profiles by exposing cells to pharmaceutical compounds and other chemicals, and then determining levels of expression of multiple genes in the cells. The company said these methods can be used by pharmaceutical and biotechnology companies to test compounds for efficacy and safety.

Filed under

The Scan

Missed Early Cases

A retrospective analysis of blood samples suggests early SARS-CoV-2 infections may have been missed in the US, the New York Times reports.

Limited Journal Editor Diversity

A survey finds low diversity among scientific and medical journal editors, according to The Scientist.

How Much of a Threat?

Science writes that need for a provision aimed at shoring up genomic data security within a new US bill is being questioned.

PNAS Papers on Historic Helicobacter Spread, Brain Development, C. difficile RNAs

In PNAS this week: Helicobacter genetic diversity gives insight into human migrations, gene expression patterns of brain development, and more.